US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revelation Biosciences, Inc.

0.0119

-0.0002-1.65%

Volume:6.97K

Turnover:71.13

Market Cap:- -

PE:- -

High:0.0119

Open:0.0111

Low:0.0100

Close:0.0121

Loading ...

Overview Company News Filings

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

REVB Starts 2025 With Bright Future Ahead

Zacks Small Cap Research

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

REVB Start 1B Trial and Announces Split

Zacks Small Cap Research

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

REVB Gets FDA Go Ahead

Zacks Small Cap Research

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

REVB Results Set Stage for Future Growth

Zacks Small Cap Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/REVBW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"REVBW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"REVBW\",,,,,undefined,":{"symbol":"REVBW","market":"US","secType":"STK","nameCN":"Revelation Biosciences, Inc.","latestPrice":0.0119,"timestamp":1743105600000,"preClose":0.0121,"halted":0,"volume":6966,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Pre-Market Trading","change":-0.0002,"latestTime":"03-28 08:56:40 EDT","open":0.0111,"high":0.0119,"low":0.01,"amount":71.1347,"amplitude":0.157025,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743168600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0105,"volumeRatio":0.5535776729660651},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"REVBW\",,,,,undefined,":{"symbol":"REVBW","floatShares":0,"roa":"-52.93%","roe":"-264.85%","lyrEps":0,"volumeRatio":0.5535776729660651,"shares":0,"dividePrice":0,"high":0.0119,"amplitude":0.157025,"preClose":0.0121,"low":0.01,"week52Low":0.004,"pbRate":"0.00","week52High":0.0413,"institutionHeld":0,"latestPrice":0.0119,"eps":0,"divideRate":0,"volume":6966,"delay":0,"ttmEps":0,"open":0.0111,"prevYearClose":0.007,"prevWeekClose":0.0127,"prevMonthClose":0.0171,"prevQuarterClose":0.007,"fiveDayClose":0.0128,"twentyDayClose":0.0168,"sixtyDayClose":0.0089},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"REVBW\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520129517","title":"Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2520129517","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520129517?lang=en_us&edition=fundamental","pubTime":"2025-03-17 18:00","pubTimestamp":1742205600,"startTime":"0","endTime":"0","summary":"– Observed response is excellent surrogate of the potential of Gemini in target indications –。In this study, human PBMCs were primed with either Gemini or placebo followed by challenge with clinically relevant promoter molecules of inflammation including high mobility box protein-1  and lipopolysaccharide  in vitro. HMGB-1 is an endogenous damage associated molecular pattern  that is generated during tissue injury  which drives the inflammatory response. LPS is an exogenous pathogen associated molecular pattern  that is generated from a bacterial infection and drives the inflammatory response associated with infection .\"These exciting results further demonstrate the game-changing potential of Gemini to attenuate the inflammatory response to clinically relevant DAMPS and PAMPS,\" said James Rolke, Chief Executive Officer of Revelation. \"We look forward to demonstrating the same protective effect in cells collected from CKD patients, which will be an excellent s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gemini-priming-attenuates-inflammation-human-100000120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVB","REVBW","BK4139"],"gpt_icon":0},{"id":"2519889594","title":"Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2519889594","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519889594?lang=en_us&edition=fundamental","pubTime":"2025-03-13 18:00","pubTimestamp":1741860000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 13, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.Investors who wish to schedule a meeting with Revelation’s management during the conference should contact their Roth representative.Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.Company Contacts Mike PorterInvestor Relations Porter LeVay & Rose Inc.Email: mike@pl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-host-fireside-chat-100000585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4585","BK4181","HST","BK4139","REVBW","BK4588","REVB"],"gpt_icon":0},{"id":"2517772432","title":"REVB Starts 2025 With Bright Future Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517772432","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517772432?lang=en_us&edition=fundamental","pubTime":"2025-03-07 18:19","pubTimestamp":1741342740,"startTime":"0","endTime":"0","summary":"Revelation Biosciences  is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl disaccharide  and its effect on the innate immune system. The impact of PHAD on the immune system has been studied over multiple years and has been shown to have a positive effect on the human immune system. The company’s current therapeutic candidates are all based on the active ingredient PHAD, which is a synthetic version of MPLA, that is known to stimulate TLR-4. PHAD stimulation of TLR-4 leads to the production of multiple types of cytokines and chemokines which modulate the activity of the innate and adaptive immune response. Modulated activities may include stimulation and recruitment of infection fighting immune cells, down-regulation of inflammation, and/or upregulation of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revb-starts-2025-bright-future-101900815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","REVBW","REVB"],"gpt_icon":0},{"id":"2517113221","title":"Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517113221","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517113221?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:15","pubTimestamp":1741295700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 06, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results.Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients. Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients. Received net proceeds of $3.7 million from the exercise of warrants in December 2024. Gemini is an intravenously administrated, proprietary formulation of phosphorylated hexaacyl disaccharide  that reduces the damage associated with inflammation by reprograming the innate immune system to respond to stress  in an attenuated manner. Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. Revelation previously announced positive Phase 1 clinical data for intravenous treatment with Gemini. The primar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-inc-announces-financial-211500476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","REVB","REVBW"],"gpt_icon":0},{"id":"2514838742","title":"Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2514838742","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514838742?lang=en_us&edition=fundamental","pubTime":"2025-02-26 19:00","pubTimestamp":1740567600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, February 26, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the first patient in the PRIME  Phase 1b clinical study of intravenous single ascending doses of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease . The US-based, multi-site, placebo-controlled study will enroll up to forty patients in up to five cohorts.\"We are excited to announce the continued advancement of Gemini with the dosing of our first patient in the PRIME study,\" said James Rolke, Chief Executive Officer of Revelation. \"We look forward to a rapid enrollment and positive outcome of this study to bring Gemini one step closer to helping patients in need.\". Gemini is an intravenously administrated, proprietary formulation of phosphorylated hexaacyl disaccharide  that reduces the damage associated with inflammation by reprograming the innate immune system to respond to stress  in an at","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-doses-first-patient-110000612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","REVB","REVBW"],"gpt_icon":0},{"id":"2513174185","title":"Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2513174185","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513174185?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:00","pubTimestamp":1740394800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, February 24, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market LLC  formally notified the Company that REVB common stock will continue to be listed and traded on Nasdaq, as Revelation is in compliance with all requirements for continued listing.On January 21, 2025, Revelation announced the commencement of its PRIME  Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease . The U.S. multi-site placebo-controlled study will enroll up to 40 patients in five cohorts of single escalating doses.Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-inc-receives-continued-110000141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","SQQQ","REVB","USJW.SI","QLD","TQQQ","TSYW.SI","QID","IE00BGHQF748.EUR","BK4585","BK4139","NDAQ","LU2210150020.SGD","REVBW","NQmain","BK4588","USAW.SI",".IXIC","LU2095319765.USD","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","NVIW.SI","IE00BKPKM429.USD","PSQ","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2507465825","title":"REVB Start 1B Trial and Announces Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2507465825","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507465825?lang=en_us&edition=fundamental","pubTime":"2025-01-29 19:05","pubTimestamp":1738148700,"startTime":"0","endTime":"0","summary":"Revelation Biosciences  announced that it has initiated its US based Phase 1b clinical study to evaluate the potential of Gemini as a preconditioning treatment in patients with chronic kidney disease . This is extremely good news for the progression of this important treatment that has showed so much promise in earlier tests as we’ve discussed before.According to the company, the multi-site, placebo-controlled Phase 1b clinical study will enroll up to 40 subjects in up to 5 cohorts. The primary endpoint is evaluation of the safety and tolerability of a single dose of Gemini in patients with CKD. Secondary and exploratory endpoints will assess the pharmacokinetics, and the potential of Gemini to mobilize and attenuate the innate immune response to stress by measuring several predictive biomarkers of efficacy. The company also noted that topline data from the trial is expected to be announced mid-2025.We are under no illusions that it’s easy to bring new therapies all the way to commerci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revb-start-1b-trial-announces-110500884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","REVB","REVBW"],"gpt_icon":0},{"id":"2505585348","title":"Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505585348","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505585348?lang=en_us&edition=fundamental","pubTime":"2025-01-24 19:00","pubTimestamp":1737716400,"startTime":"0","endTime":"0","summary":"The reverse stock split is intended to increase the market price per share of the Company’s common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company’s warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company’s equity incentive plans.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-inc-announces-1-110000847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVB","BK4139","REVBW"],"gpt_icon":0},{"id":"2505228506","title":"Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2505228506","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505228506?lang=en_us&edition=fundamental","pubTime":"2025-01-21 19:00","pubTimestamp":1737457200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, January 21, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that it has started its PRIME  Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease . The US based multi-site placebo-controlled study will enroll up to forty patients in five cohorts of single escalating doses.\"I am delighted to see the Revelation teams’ hard work culminating with the start of the PRIME study.\" said James Rolke, Chief Executive Officer of Revelation. \"We look forward to the results and plan to educate the public over the next few months on the importance of the planned biomarkers as it relates to CKD treatment and prevention of AKI.\". Gemini is an intravenously administrated, proprietary formulation of phosphorylated hexaacyl disaccharide  that reduces the damage associated with infl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-starts-prime-phase-110000546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVB","BK4139","REVBW"],"gpt_icon":0},{"id":"2503377662","title":"Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503377662","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503377662?lang=en_us&edition=fundamental","pubTime":"2025-01-13 19:00","pubTimestamp":1736766000,"startTime":"0","endTime":"0","summary":"– A vote for Proposal 2 saves the Company over $200,000 per year –。SAN DIEGO, January 13, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals.Please vote by calling Advantage Proxy toll free at 877-870-8565 or 206-870-8565.Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, inc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-inc-reminds-vote-110000905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVBW","BK4505","BK4528","BK4023","BK4551","LU1861559042.SGD","BK4532","REVB","BK4585","BK4139","BK4554","BK4588","ZM","LU1861558580.USD","BK4535","BK4548","BK4525"],"gpt_icon":0},{"id":"2501871372","title":"Nasdaq Grants Revelation Biosciences Inc. Continued Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2501871372","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501871372?lang=en_us&edition=fundamental","pubTime":"2025-01-06 19:00","pubTimestamp":1736161200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, January 06, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the Nasdaq Hearings Panel issued a decision letter granting Revelation’s request to continue its listing on The Nasdaq Stock Market, subject to its stock trading at or above $1.00 for at least ten consecutive trading days by February 14, 2025.Additionally, the Nasdaq Hearings Panel confirmed that the Company has regained compliance with the Equity Requirement of Listing Rule 5550 for which the Company was issued a notice of delisting for failure to comply with Equity Requirement of Listing Rule 5550 on August 14, 2024.\"We are very thankful to the Nasdaq Hearings Panel for recognizing the significant progress made following the tumultuous time for the Company post SPAC merger,\" said James Rolke, Chief Executive Officer of Revelation. \"Now that our obligations from the SPAC merg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nasdaq-grants-revelation-biosciences-inc-110000673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","NDAQ","MNQmain","PSQ","USJW.SI","TQQQ",".IXIC","IE00B3QW5Z07.USD","USAW.SI","IE00BKPKM429.USD","NQmain","REVB","SQQQ","LU2095319765.USD","BK4139","LU2210150020.SGD","BK4112","QLD","BK4588","QID","NVIW.SI","TSYW.SI","BK4585","LU2210149790.SGD","IE00B64PRP62.GBP","REVBW"],"gpt_icon":1},{"id":"2488910932","title":"Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2488910932","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488910932?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:38","pubTimestamp":1733233080,"startTime":"0","endTime":"0","summary":"SAN DIEGO, December 03, 2024----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,064,040 shares of common stock, issued by the Company on August 22, 2024 , at the exercise price of $1.00 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-3 . The closing of the offering is expected to occur on or about December 3, 2024, subject to satisfaction of customary closing conditions.Roth Capital Partners is acting as the Company’s financial advisor for this transaction.This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-inc-announces-exercise-133800412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVBW","REVB","BK4139"],"gpt_icon":1},{"id":"2488889950","title":"REVB Gets FDA Go Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2488889950","media":"Zacks Small Cap Research","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488889950?lang=en_us&edition=fundamental","pubTime":"2024-12-02 22:10","pubTimestamp":1733148600,"startTime":"0","endTime":"0","summary":"Revelation Biosciences  announced that the FDA has accepted the company’s IND application for Gemini. This announcement allows the Company to initiate its US based Phase 1b clinical study to evaluate the potential of Gemini as a preconditioning treatment in patients with chronic kidney disease . This is extremely good news for the progression of this important treatment that has showed so much promise in earlier tests as we’ve discussed before.We are under no illusions that it’s easy to bring new therapies all the way to commercialization and Revelation will undoubtedly face challenges, but we believe that REVB is worth a look by investors due to the potential of the treatments being investigated, the science that has already been established behind those treatments, and the experienced management team the company has, headlined by the CEO who has overseen six INDs and two marketing approvals—experience we believe is needed to shepherd these treatments through the gauntlet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revb-gets-fda-ahead-141000143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVB","BK4139","REVBW"],"gpt_icon":0},{"id":"2488950835","title":"Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2488950835","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488950835?lang=en_us&edition=fundamental","pubTime":"2024-12-02 19:00","pubTimestamp":1733137200,"startTime":"0","endTime":"0","summary":"-Phase 1b Study in CKD Patients to begin early 2025-. SAN DIEGO, December 02, 2024----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the United States Food and Drug Administration  has accepted its investigational new drug  application for Gemini. This game changing milestone allows the Company to initiate its US based Phase 1b clinical study to evaluate the potential of Gemini as a preconditioning treatment in patients with chronic kidney disease .Positive data from the Phase 1b study will enable a Phase 2 study of Gemini as a preconditioning treatment in patients with CKD to reduce the incidence, duration, and severity of acute kidney injury  in patients undergoing coronary artery bypass graft  and/or cardiac valve surgery.Gemini is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-inc-announces-fda-110000557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVB","BK4139","REVBW"],"gpt_icon":0},{"id":"2482740947","title":"Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2482740947","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482740947?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:00","pubTimestamp":1731409200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, November 12, 2024----Revelation Biosciences, Inc.  , a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced it has successfully completed the GMP manufacture of Gemini drug product to support anticipated clinical studies in the United States. GMP compliant manufacturing of Gemini is a pivotal requirement for an Investigational New Drug  application with FDA. The Company intends to utilize the current supply of Gemini for the upcoming Phase 1b clinical trial in chronic kidney disease  patients as well as future Phase 2 studies.\"We are pleased to have achieved this critical milestone for the advancement of Gemini,\" said James Rolke, Chief Executive Officer of Revelation. \"We look forward to starting our Phase 1b study in CKD and anticipate top-line results including pharmacokinetic, pharmacodynamic, and safety data in the first half of 2025.\"","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5_APAb9JvShuff4BOKlyNg--~B/aD0zMTU7dz03ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4b03f2dc6e334d14b7d37fa53360e0e5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5_APAb9JvShuff4BOKlyNg--~B/aD0zMTU7dz03ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4b03f2dc6e334d14b7d37fa53360e0e5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-inc-completes-gmp-110000982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVBW","BK4139","REVB"],"gpt_icon":0},{"id":"2482734970","title":"REVB Results Set Stage for Future Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2482734970","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482734970?lang=en_us&edition=fundamental","pubTime":"2024-11-11 18:00","pubTimestamp":1731319200,"startTime":"0","endTime":"0","summary":"Revelation Biosciences  announced its 3Q2024 financial results which showed, after exciting testing announcements detailed below, good cash on hand that the company says is at least enough to finance operations into 2025. Clinical stage companies are often in a cash crunch, and we are pleased to see that Revelation is in solid shape for the foreseeable future. Cash on the balance sheet stood at $6.5 million at the end of 3Q, while improved expense discipline improved the bottom line, as the loss of $0.84 per share bested our estimates and was much improved from the previous quarter.Even more exciting was that the company released data on key circulatory biomarkers from the study that showed","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SfPo4Sh4Ic4uP08CRLvljQ--~B/aD04NjY7dz0xMjcwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/9f4210593de89a8769c557d4f582b0a9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SfPo4Sh4Ic4uP08CRLvljQ--~B/aD04NjY7dz0xMjcwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/9f4210593de89a8769c557d4f582b0a9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revb-results-set-stage-future-100000678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVB","BK4139","SSI","REVBW"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":1,"totalSize":17}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/REVBW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"REVBW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"REVBW\",market:\"US\",delay:false,,,undefined,":{}}}